United States - English - NLM (National Library of Medicine)

precision nuclear llc - ammonia n-13 (unii: 9oqo0e343z) (ammonia n-13 - unii:9oqo0e343z) - ammonia n-13 260 mci in 1 ml - ammonia n 13 injection usp is indicated for diagnostic positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. none pregnancy category c animal reproduction studies have not been conducted with ammonia n 13 injection. it is also not known whether ammonia n 13 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ammonia n 13 injection should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from ammonia n 13 injection, use alternative infant nutrition sources (e.g., stored breast milk or infant formula) for 2 hours (> 10 half-lives of radioactive decay for n 13 isotope) after administration of the drug or avoid use of the drug, taking

United States - English - NLM (National Library of Medicine)

ionetix corporation - ammonia n-13 (unii: 9oqo0e343z) (ammonia n-13 - unii:9oqo0e343z) - ammonia n 13 injection is indicated for diagnostic positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. none pregnancy category c animal reproduction studies have not been conducted with ammonia n 13 injection. it is also not known whether ammonia n 13 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ammonia n 13 injection should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from ammonia n 13 injection, use alternative infant nutrition sources (e.g. stored breast milk or infant formula) for 2 hours (>10 half-lives of radioactive decay for n 13 isotope) after administration of the drug or avoid use of the drug, taking into account the importance of the drug to the mother. the safety and effectiveness of ammonia n 13 injection has been established in pediatric patients based on known metabolism of ammonia, radiation dosimetry in the pediatric population, and clinical studies in adults [see dosage and administration (2.4)].

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - lenograstim 13.4 miu - powder for injection - 13.4 miu - active: lenograstim 13.4 miu excipient: arginine hydrochloric acid mannitol methionine phenylalanine polysorbate 20

United States - English - NLM (National Library of Medicine)

wyeth pharmaceutical division of wyeth holdings llc - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 54ec0se5pz) (streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:54ec0se5pz), streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 2vf3v7175u) (streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:2vf3v7175u), streptococcus pneumoniae type - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen 2.2 ug in 0.5 ml - in children 6 weeks through 5 years of age (prior to the 6th birthday), prevnar 13® is indicated for: in children 6 years through 17 years of age (prior to the 18th birthday), prevnar 13 is indicated for: risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data on prevnar 13 administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. a developmental toxicity study has been performed in female rabbits administered prevnar 13 prior to mating and during gestation. each dose was approximately 20 times the human dose. this study revealed no evidence of harm to the fetus due to prevnar 13 (see 8.1 data). data animal in a developmental toxicity study, female rabbits were administered prevnar 13 by intramuscular injection twice prior to mating (17 days an

United States - English - NLM (National Library of Medicine)

encube ethicals private limited - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - clobetasol propionate cream usp, 0.05% is super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g /week because of the potential for the drug to suppress the hypothalamic-pituitary- adrenal (hpa) axis. use in pediatric patients under 12 years of age is not recommended. as with other highly active corticosteroids, therapy should be discontinued when control has been achieved. if no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. clobetasol propionate cream usp, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmalink store united states of america - 22.2 ml spray bottle - spray - 13% - obstetrics,gynaecology,urinary-tract-erectile and ejaculatory conditions

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - chlorhexidine acetate 0.05%{relative} - antiseptic solution - 0.05% w/v - active: chlorhexidine acetate 0.05%{relative} excipient: glacial acetic acid methylthioninium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

carsl consulting - macrogol 3350 13.125 g;  ; potassium chloride 46.6mg; sodium bicarbonate 178.5mg; sodium chloride 350.7mg - powder for oral solution - 13.8 g - active: macrogol 3350 13.125 g   potassium chloride 46.6mg sodium bicarbonate 178.5mg sodium chloride 350.7mg excipient: acesulfame lemon & lime. trusil 463842 - for effective relief from constipation, treatment of chronic constipation. movicol is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon confirmed by physical examination of abdomen and rectum.

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - follitropin alfa - injection, solution - 22.23 mcg - follitropin alfa 22.23 mcg

United States - English - NLM (National Library of Medicine)

sofie co. - ammonia n-13 (unii: 9oqo0e343z) (ammonia n-13 - unii:9oqo0e343z) - ammonia n-13 37.5 mci in 1 ml - ammonia n 13 injection, usp is indicated for diagnostic positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. none pregnancy category c animal reproduction studies have not been conducted with ammonia n 13 injection. it is also not known whether ammonia n 13 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. ammonia n 13 injection should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from ammonia n 13 injection, use alternative infant nutrition sources (e.g. stored breast milk or infant formula) for 2 hours (>10 half-lives of radioactive decay for n 13 isotope) after administration of the drug or avoid use of the drug, taking i